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Background: Cryoglobulinemia is an immune-complex-mediated small vessel vasculitis that
classically involves the skin, kidneys and peripheral nerves. Antiphospholipid syndrome
(APS) is an autoimmune hypercoagulable disorder which causes blood vessel thrombosis. It
can  present as a multi-organ microthrombotic disorder which is called catastrophic APS.
Objective: In this case series we aim to describe the diagnostic and management challenges
that arise when these two severe disorders simultaneously present in the same patient.
Methods: We  describe four patients who were admitted to our hospital due to multi-organ
life  threatening damage mediated by cryoglobulinemic vasculitis with concurrent APS.
Results: Clinical manifestations included leg ulcers, livedo reticularis, renal failure, and
peripheral neuropathy. Suggested etiologies for the combined syndromes were hepatitis
C,  systemic lupus erythematosus and myeloproliferative disease rectal maltoma. All of
our  patients were treated with anticoagulation, high-dose corticosteroids, rituximab, intra-
venous gammaglobulins and plasma exchange.
Conclusion: The rare association of severe or catastrophic APS with cryoglobulinemia in
patients should be considered by physicians who treat patients with multi-organ ischemiaor  necrosis.
© 2014 Elsevier Editora Ltda. All rights reserved.DOI of original article: http://dx.doi.org/10.1016/j.rbr.2014.09.005.
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2255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Correlac¸ão  entre  a  síndrome  antifosfolipídica  e  a  crioglobulinemia:  série
de  quatro  casos  e  revisão  da  literatura
Palavras-chave:
Crioglobulinemia
Síndrome antifosfolipídica
Vasculite
r  e  s  u  m  o
Introduc¸ão: A crioglobulinemia é uma vasculite de pequenos vasos mediada por imuno-
complexos que normalmente envolvem a pele, os rins e os nervos periféricos. A síndrome
antifosfolipídica (SAF) é um transtorno da hipercoagulabilidade autoimune que provoca
trombose dos vasos sanguíneos. Pode se manifestar como um distúrbio microtrombótico
que  afeta múltiplos órgãos, denominado SAF catastróﬁca.
Objetivo: Esta série de casos objetiva descrever os desaﬁos de diagnóstico e tratamento que
surgem quando esses dois graves transtornos estão presentes simultaneamente no mesmo
paciente.
Métodos: Foram descritos quatro pacientes internados em nosso hospital em decorrência
de  danos graves a múltiplos órgãos mediados pela vasculite crioglobulinêmica com SAF
concomitante.
Resultados: As manifestac¸ões clínicas incluíram úlceras de perna, livedo reticular, insuﬁciên-
cia  renal e neuropatia periférica. As etiologias sugeridas para a combinac¸ão de síndromes
foram a hepatite C, o lúpus eritematoso sistêmico e a doenc¸a mieloproliferativa retal asso-
ciada a linfoma de zona marginal tipo células B. Todos os pacientes foram tratados com
anticoagulantes, altas doses de corticosteroides, rituximabe, gamaglobulinas intravenosas
e  troca de plasma.
Conclusão: A rara associac¸ão entre a SAF grave ou catastróﬁca e a crioglobulinemia deve ser
considerada por médicos que atendem pacientes com isquemia ou necrose de múltiplos
órgãos.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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ryoglobulins (CG) are immune complexes comprised of
mmunoglobulins (IGs), either poly- or monoclonal, that binds
ther IGs that are deposited in small blood vessels and
lomeruli upon exposure to cold temperatures. The preva-
ence of clinically signiﬁcant cryoglobulinemia has been
stimated at approximately 1 in 100,000.1–4 The presence of
he CG-containing immune complexes often results in small
o medium vessel vasculitis.5–7 The Brouet classiﬁcation of
ryoglobulinemia is based on the composition of the CGs:8
ype I – isolated monoclonal IGs; Type II – Mixed CGs –
mmune complexes formed by monoclonal IGs, this is the
ost common type and associated with HCV and HIV; Type
II – Mixed CGs – immune complexes formed by polyclonal
Gs.
Although most of the patients with cryoglobulinemia
emain asymptomatic, the disease may involve mainly the
kin, kidneys and peripheral nervous system. Type I cryo-
lobulinemia manifestations are usually due to hyperviscosity
nd/or thrombosis, including Raynaud’s phenomenon, dig-
tal ischemia and gangrene, livedo reticularis, purpura and
eurologic symptoms. In contrast, type II and III cryo-
lobulinemia causes arthralgia, fatigue, myalgia, palpable
urpura, peripheral neuropathy as well as membranopro-
iferative glomerulonephritis.9–11 Antiphospholipid syndrome
APS) is an autoimmune hypercoagulable disorder charac-
erized by arterial and/or venous thrombosis, pregnancy
orbidity including recurrent fetal loss and eclampsia in the
resence of elevated levels of anti-cardiolipin (ACL) (≥40 U)and/or 2 glycoprotein I IgG and/or IgM antibody (>99th per-
centile) and/or lupus anticoagulant (LAC).
Antiphospholipid antibodies (aPL). According to the lab-
oratory revised criteria the anti-cardiolipin (ACL) IgG, IgM
antibody and/or anti-2 glycoprotein I (2GPI) IgG, IgM (accord-
ing to our laboratory kit, above >20 U) and/or positive test
for lupus anticoagulant (LAC) tested positive on 2 consecu-
tive occasions at least 12 weeks apart.12–15 An association
between cryoglobulinemia and APS has been previously
reported (Table 1).16–20 In this study, we describe four patients
who presented with manifestations of both cryoglobulinemic
vasculitis21 and APS.
Case  presentation
Case  1
A 51-year-old female was presented with diabetes mellitus
type 2 and hypertension. In 1997 she suffered from sudden
loss of vision in right eye. In 2001 she developed livedo reticu-
laris of both lower extremities. Laboratory tests revealed urine
stick test protein level of 500 mg/dL, CRP level was 54.85 mg/dL
(upper normal range – 0.5 mg/dL), and positive aPL serology
(2 tests taken 12 weeks apart – values are listed in Table 2).
Also, positive ANA titer (1:160), positive cryoﬁbrino-
gen IgG and IgM kappa, and IgM cryoglobulins type 1
(215 mg/L, reference range 0–60 mg/L) were revealed. Kid-
ney biopsy demonstrated evidence of membranoproliferative
glomerulonephritis. The patient was treated with 1 g methyl-
prednisolone followed by a 6-month period of tapering down
4  r e v b r a s r e u m a t o l . 2 0 1 6;5 6(1):2–7
Table 1 – Laboratory characteristics of our patients case series.
Patient
num.
Age Sex Etiology ACL
antibodya,b
Anti-2GPI
antibodya,b
LACa,c ANA Anti-
DsDNA
RF  Cryoglobulins mono-
clonal/polyclonal/
mixed
1 51 F Idiopathic +
IgM = 153 U,
109 U
IgG = 98 U,
115 U
+
IgM = 100 U,
73 U
IgG = 81 U,
49 U
-  + - NS IgM kappamonoclonal
2 66 M Multiple
myeloma
−  +
IgG = 78 U,
122 U
−  + − − IgG kappamonoclonal
3 40 M HCV
and SLE
+
IgM = 132 U,
49 U
+
IgM  = 67 U,
50 U
+  + + − Mixed
4 65 F MALT
lymphoma
+
IgG  = 91 U,
73 U
+
IgG  = 56 U,
62 U
+  + − + Mixed
ACL, anticardiolipin; anti 2GPI, anti-2  glycoprotein I; LAC, lupus anti coagulant; ANA, anti nuclear antibody; anti DsDNA, anti double strand
DNA; RF, rheumatic factor; HCV, hepatitis C virus
a 2 values for 2 tests taken 12 weeks apart.
b ACL and anti- 2GPI IgG, IgM antibody assayed by ELISA according to manufacturer’s guidelines.
c Lupus anti coagulant tested with RVVT, Positive values above 1.5 ratio.
Table 2 – Summary of case studies and series of clinical and laboratory characteristic in patient with antiphospholipid
syndrome and cryoglobulinemia.
Study Study design Co morbidity Clinical
presentation
Treatment Cryoglobulins
monoclonal/
polyclonal/
mixed
aPL
antibodies
(ACL, 2GPI),
LAC
Yancey et al.
(1990)
Case study –
1 patient –
35-years-old
female
SLE Livedo reticularis,
renal failure,
arthralgia,
2 miscarriages
NS  Serum
cryoglobulins
were positive
(values NS)
ACL  IgG –
200GPLU/mL
(normal
< 5.5 GPLU/mL)
Asherson et al.
(1992)
Case series –
2 patients
Hereditary
complement
factor 2
syndrome,
Sjögren’s
syndrome
Livedo reticularis NS Serum cryol-
globulins
were positive
(values NS)
Patients 1 ACL IgG
14.4 units
(n ≤ 5 units).
Patients 1 ACL IgG
10.2 units
(n ≤ 5 units)
Hanly and Smith
(2000)
Case series –
5 patients –
4/5 females
mean age
−53.2 ± 2.9 y
NS 3 of them
had SLE
Venous thrombosis –
2 patients.
Arterial thrombosis –
1 patients.
Thrombocytopenia –
2 patients
NS  All patients,
one patient
had IgM
kappa – type
1, the remain
patients had
mixed type III
(values NS).
All  patients had
positive LAC. And
4/5 had positive IgG
ACL (values NS).
Andrejevic et al.
(2003)
Case study –
1 patient –
69-years-old
female
NHL Leg ulcers Aspirin,
heparin,
prednisone
Mixed type II
Cryocit@ 12%
ACL IgG –
92 GPLU/mL (normal
< 5.5 GPLU/mL)
Chang et al.
(2006)
Case study –
1 patient –
14-year-old
boy
Partial
DiGeorge
syndrome
and recent
streptococcal
infection
Pulmonary embolus,
proliferative
glomerulonephritis
Warfarin,
prednisone,
and
mycopheno-
late
mofetil
Mixed type III
Cryocit@ 10%
LAC was borderline
positive; ACL IgM –
17 PLU (normal < 10);
Anti-2GPI IgM –
36 U/mL
(normal < 10 U/mL)
NHL, non-Hodgkin’s lymphoma; ACL, anticardiolipin; Anti 2GPI, anti-2  glycoprotein; LAC, lupus anti-coagulant; NS, non-stated; Cryocrit@,
percentage of packed cryoglobulins referred to total serum after centrifugation at 4 ◦C.
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150,000–450,000 K/L).
Treatment with hydrocortisone (100 mg  × 3 d) and anti-r e v b r a s r e u m a
o 60 mg  prednisone. 3 years later, the patient was admitted
o the hospital with purpura, ulcers in her lower extremities
nd splinter hemorrhages of the nails.
She showed evidence of nephrotic syndrome with urine
rotein of 5 g/24 h and acute renal failure (serum creatinine
evel was 2.8 mg/dL). Skin biopsy demonstrated a thrombotic
vent without evidence of vasculitis. Urine was positive for
ence-Jones protein. CGs and Cryoﬁbrinogen were positive
315 mg/L, reference range 0–60 mg/L, and 3 g/L; upper normal
ange – 0.5 g/L, respectively). Hepatitis B and C were both neg-
tive. Bone marrow biopsy showed no evidence of myeloma
r other lymphoproliferative disease.
The patient was treated with 60 mg  prednisone and war-
arin (dose adjusted according to INR goal of 2–3) with
mprovement of cutaneous ﬁndings and partial normalization
f creatinine level (1.7 mg/dL). Urine protein was 2.3 g/24 h.
Two years later she presented with dyspnea, hemoptysis,
nemia, lower extremities purpura and elevated creatinine
evel. Chest CT revealed diffuse alveolar hemorrhage. The
reatment with warfarin was then discontinued. Creatinine
evel was 4.62 mg/dL with urine protein of 7.125 g/24 h and
BC casts were observed on microscopic examination of urine.
ryoﬁbrinogen IgG kappa was positive (2 g/L, upper normal
ange 0.5 g/L). CGs were negative (32 mg/L, reference range
–60 mg/L) and aPL were positive. Treatment was initiated with
ialysis, hydrocortisone (100 mg  × 3 d), 2 courses of rituximab
1 g) infusions and plasmapheresis. The patient died in the
ntensive care unit 2 weeks after being admitted to the hospital
ue to sepsis.
ase  2
 66-year-old male with diabetes mellitus type 2. In 2003 he
resented with lower extremity ulcers (mainly in toes). He was
reated with prednisone (60 mg  × 1 d) with tapering down for
 months and IV iloprost (prostacyclin PGI2 analog). Serology
or Hepatitis B was positive (HBs and HBe were positive)
nd anti-viral treatment with Lamivudine (nucleoside ana-
og reverse transcriptase inhibitor) was initiated (300 mg  × 1 d).
nder this treatment the patient’s ulcers improved.
Three years later he presented with ischemic ulcers in
 number of toes and purpura in both lower extremities.
kin biopsy revealed fresh bleeding in dermis with mononu-
lear inﬁltrate around blood vessels. One blood vessel was
urrounded by polymorphonuclear inﬁltrate and in some
essels thrombi were evident. Monoclonal CGs IgG light
hain kappa type 1 was found (152 mg/L, reference range
–60 mg/L). C3 and C4 levels were normal. Bone marrow biopsy
evealed 7–8% plasma cells positive for IgG kappa. Most of
he plasma cells were monoclonal for IgA. The patient was
reated for type 1 cryoglobulinemia with monoclonal gam-
opathy with plasmaphersis and IV cyclophosphamide for
 months.
Six years after the initial presentation he developed left
emiparesis. Laboratory tests were positive twice, 12 weeks
part, for aPL serology (Table 2) and ANA titer was 1:160. The
atient was diagnosed with APS and treated with warfarin.
One year later, he presented with right 3rd ﬁnger necro-
is and palpable purpura on left lower limb. He was treated
ith a sympathetic block, hydrocortisone (100 mg  × 3 d), 2 0 1 6;5 6(1):2–7  5
plasmapheresis, IV iloprost and warfarin. Bone marrow biopsy
demonstrated positivity for CD138 with plasma cells secreting
lambda and kappa light chains.
In 2011 a bone marrow biopsy showed 15% plasma
cells positive for IgG kappa light chain secretion (multi-
ple myeloma-clonal plasma cells >10% on bone marrow
biopsy). The patient was positive for CGs (343 mg/L, refer-
ence range 0–60 mg/L). Therefore, the patient was diagnosed
with multiple myeloma and began treatment with melphalan,
prednisone and bortezomib.
Case  3
A 40-year-old male known to be a hepatitis C (HCV) carrier was
diagnosed with systemic lupus erythematosus (SLE) in 1999.
The disease presentation included malar rash, leucopenia,
thrombocytopenia, photosensitivity, arthritis and alopecia.
Laboratory: analysis showed that ANA and dsDNA were pos-
itive (ANA of 1:160, dsDNA of 25%, normal range 0–20%). The
patient was treated with hydroxychloroquine and prednisone
(in varying dosages). Five years later he presented with right
foot gangrene which necessitated below knee amputation and
CVA with right hemiparesis. CT scan revealed left parietal
infarct. In laboratory testing, there was positivity for aPL
(2 tests taken 12 weeks apart – values are listed in Table 2)
and mixed cryoglobulinemia (type 2) – 511 mg/L (reference
range 0–60 mg/L). He was treated with warfarin, hydroxy-
chloroquine (200 mg  × 2 d) and prednisone (60 mg)  with three
months tapering down.
Case  4
A 65-year-old female who had been suffering from intermit-
tent purpura for nearly 30 years and in the last few years
began complaining of numbness of the lower limb. EMG  stud-
ies revealed severe axonopathy. CT of the spine showed only
spondylolisthesis in L5-S1. Laboratory was positive for mixed
cryoglobulinemia – CGs level of 215 mg/L (reference range
0–60 mg/L) and ANA titer of 1:160. C3 and C4 levels were very
low and serology’s for hepatitis C and B were negative. aPL
serology was positive (2 tests taken 12 weeks apart – Table 2).
The patient underwent an abdominal CT which revealed an
inﬂamed terminal ileum.
Colonoscopic examination showed macroscopic appear-
ance of proctitis and the biopsy was compatible with
mucosa-associated lymphoid tissue (MALT) lymphoma. Treat-
ment with rituximab, cyclophosphamide and prednisone was
initiated. A week later, the patient was re-admitted to the
hospital due to livedo reticularis, purpura, lower extremities
ulcers and confusion. Head CT showed no infracts. Labora-
tory tests revealed microangiopathic anemia (schistocytes on
blood smear) and thrombocytopenia of 70 K/L  (normal rangecoagulation with IV heparin was initiated. Under this
treatment, the confusion improved partially, but the leg ulcers
progressed to anaerobic infection and then sepsis, eventually
leading to above knee amputation of his left leg.
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Discussion
In the case series presented here we describe four patients
with cryoglobulinemic vasculitis present concurrently with
clinical features of APS. All our patients suffered from recalci-
trant leg ulcers and skin necrosis, resulting in amputations in
2 out of the 4 patients.
In a case-series of 200 consecutive patients with APS (either
primary APS or APS secondary to SLE), skin ulcers and/or
necrosis was reported in only 2% of the patients,22 whereas
it occurs in 10% of patients with cryoglobulinemia.23 In our
series, all four patients suffered from skin ulcers and necrosis,
most probably secondary to the synergistic effect of cryoglob-
ulin and thrombosis-mediated cutaneous ischemia as result
of small and medium-sized blood vessel occlusion.
Our case-series is in accordance with three case-series of
patients with both cryoglobulinemia and APS.16–18 This sug-
gests that the concurrent presentation of overlapping clinical
features due to cryoglobulinemia and APS should be assessed
in patients with severe ischemic cutaneous lesions. The eti-
ology of cryoglobulinemia and APS in the Hanly and Smith16
and Yancey et al.17 series was mostly due to SLE. In our case
series, two patients (2, 4) suffered from lymphoproliferative
disease, one patient was diagnosed with primary APS and one
had HCV and SLE.
Like patients 2 and 4 in our series who  had lymphopro-
liferative disease, Andrejevic et al.,18 described patients with
non-Hodgkins lymphoma, monoclonal cryoglobulinemia and
ACL antibodies with vasculitis. They concluded that patients
with lymphoid malignancies and ACL antibodies in their
cryoprecipitate may be at risk for developing clinical mani-
festations of APS.
Chang et al.19 also described a patient with DiGeorge
syndrome who  developed mixed cryoglobulinemia, APS and
systemic vasculitis after a streptococcal infection.
Asherson et al.,20 described two sibling with hereditary
complement factor 2 deﬁciencies. They both presented with
cutaneous vasculitis, cryoglobulinemia and ACL antibodies.
After removal of the cryoprecipitate from the serum sample
of the two patients the serum antibodies of ACL fell. This
implicates the incorporation of ACL antibodies within cryo-
precipitates.
The formation of 2 glycoprotein I and anti-2 glycoprotein
I antibody immune-complexes has been documented.24
However, Bardin et al.25 described 55 patients with APS
who  were positive for both cryoglobulinemia and IgM phos-
phatidylethanolamine antibodies (aPE). Determination of IgM
aPE levels was made before and after removal of cryoprecip-
itate from the serum. Of the 55 patients, 52 (95%) showed
no signiﬁcant difference of IgM aPE levels before and after
cryoprecipitation. They concluded that in most cases cryo-
precipitation does not interfere with IgM aPE level. Thus, IgM
aPE does not appear to be involved in the formation of the
cryoprecipitate.
Our study is not without limitations; it includes only a
small number of patients, with different types of cryoglobu-
lins, different isotypes of antiphospholipid antibodies, as well
as different co-morbidities. In spite of this heterogeneity, all
four patients had hard to treat ischemic cutaneous ulcers and . 2 0 1 6;5 6(1):2–7
this is the most important manifestation related to the pre-
sentation of the two syndromes presented together.
We recommend ruling out the presence of APS in patients
with cryoglobulinemic vasculitis recalcitrant to the standard
therapy and vice versa.
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